跳至主要内容
临床试验/NL-OMON31343
NL-OMON31343已完成不适用

Transient myeloproliferative disease in children with Down syndrome Part A: Screening newborns with Down syndrome for TMD Part B: Treatment and follow-up of children with Down syndrome and TMD - TMD in children with Down syndrome

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 811 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
811

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 11(—)

入选标准

  • Inclusion criteria part A:
  • - Newborns with Down syndrome born in the Netherlands
  • - Diagnosis between 01-07-2007 and 01-07-2012
  • - Age at peripheral blood sampling below 4 weeks
  • - Patients with demonstrable transient myeloid leukemia elsewhere are also eligible, even if no blasts can be detected in the peripheral blood
  • - signed informed consent;Inclusion criteria part B:
  • - proven TMD
  • - Down syndrome
  • - detectable GATA1-mutation in leukemic cells
  • - age below 3 months
  • - infromed consent

排除标准

  • Key exclusion criteria, part A:
  • - no consent,
  • - no confirmation of diagnosis of Down syndrome,
  • - complications which prohibit the analysis of a peripheral blood sample.;Key exclusion criteria, part B:
  • - complications or underlying disease that interferes with the possibility to treat
  • - presence of another hematological disease

研究者

相似试验